Abstract
Nucleoside monophosphates (NMPs) are the first nucleotides required for the conversion of nucleosides into nucleoside triphosphates. Biocatalysis can offer an environmentally sustainable route to NMPs, but process development is a key consideration towards ensuring full efficiency. Herein we demonstrate a continuous biocatalytic platform using a promiscuous nucleoside kinase, DmDNK, to enable scalable production of a panel of non-natural NMPs in flow. The system takes advantage of enzyme immobilization to enable a dual-enzyme cascade for in situ ATP recycling, improved enzymatic productivity versus batch and accessing multi-milligram scale production of several important NMPs; isolated yields exceed 70% for 2′-deoxy-2′-fluorouridine, cytarabine and gemcitabine NMPs, with space time yields all over 22.5 g L-1 h-1. This platform provides a basis for the expansion of biocatalytic NMP production towards a sustainable delivery of these essential building blocks, including those underpinning to therapeutically relevant nucleoside triphosphates.
Supplementary materials
Title
Supporting information
Description
Contains all experimental detail and characterisation data
Actions